151 related articles for article (PubMed ID: 31785228)
1. Nucleostemin promotes hepatocellular carcinoma by regulating the function of STAT3.
Zhang X; Lv J; Luo H; Liu Z; Xu C; Zhou D; Tang L; Zhang Z; Liu J; Xiao M; Yao Y; Qu L; Lu C
Exp Cell Res; 2020 Feb; 387(1):111748. PubMed ID: 31785228
[TBL] [Abstract][Full Text] [Related]
2. STAT3 aggravates TGF-β1-induced hepatic epithelial-to-mesenchymal transition and migration.
Wang B; Liu T; Wu JC; Luo SZ; Chen R; Lu LG; Xu MY
Biomed Pharmacother; 2018 Feb; 98():214-221. PubMed ID: 29268242
[TBL] [Abstract][Full Text] [Related]
3. Long non-coding RNA FEZF1-AS1 promotes cell invasion and epithelial-mesenchymal transition through JAK2/STAT3 signaling pathway in human hepatocellular carcinoma.
Wang YD; Sun XJ; Yin JJ; Yin M; Wang W; Nie ZQ; Xu J
Biomed Pharmacother; 2018 Oct; 106():134-141. PubMed ID: 29957463
[TBL] [Abstract][Full Text] [Related]
4. Coexpression of gene Oct4 and Nanog initiates stem cell characteristics in hepatocellular carcinoma and promotes epithelial-mesenchymal transition through activation of Stat3/Snail signaling.
Yin X; Zhang BH; Zheng SS; Gao DM; Qiu SJ; Wu WZ; Ren ZG
J Hematol Oncol; 2015 Mar; 8():23. PubMed ID: 25879771
[TBL] [Abstract][Full Text] [Related]
5. Predictive value of intratumour inflammatory cytokine mRNA levels of hepatocellular carcinoma patients and activation of two distinct pathways govern IL-8 induced epithelial-mesenchymal transition in human hepatic cancer cell lines.
Peng S; Chen Y; Gong Y; Li Z; Xie R; Lin Y; Zou B; Li J; Zeng L
Cytokine; 2019 Jul; 119():81-89. PubMed ID: 30903867
[TBL] [Abstract][Full Text] [Related]
6. Endoplasmic reticulum resident oxidase ERO1-Lalpha promotes hepatocellular carcinoma metastasis and angiogenesis through the S1PR1/STAT3/VEGF-A pathway.
Yang S; Yang C; Yu F; Ding W; Hu Y; Cheng F; Zhang F; Guan B; Wang X; Lu L; Rao J
Cell Death Dis; 2018 Oct; 9(11):1105. PubMed ID: 30377291
[TBL] [Abstract][Full Text] [Related]
7. New insight into BIRC3: A novel prognostic indicator and a potential therapeutic target for liver cancer.
Fu PY; Hu B; Ma XL; Yang ZF; Yu MC; Sun HX; Huang A; Zhang X; Wang J; Hu ZQ; Zhou CH; Tang WG; Ning R; Xu Y; Zhou J
J Cell Biochem; 2019 Apr; 120(4):6035-6045. PubMed ID: 30368883
[TBL] [Abstract][Full Text] [Related]
8. TLX3 repressed SNAI1-induced epithelial-mesenchymal transition by directly constraining STAT3 phosphorylation and functionally sensitized 5-FU chemotherapy in hepatocellular carcinoma.
Wang C; Dou C; Wang Y; Liu Z; Roberts L; Zheng X
Int J Biol Sci; 2019; 15(8):1696-1711. PubMed ID: 31360112
[TBL] [Abstract][Full Text] [Related]
9. PRMT1 Promoted HCC Growth and Metastasis In Vitro and In Vivo via Activating the STAT3 Signalling Pathway.
Zhang XP; Jiang YB; Zhong CQ; Ma N; Zhang EB; Zhang F; Li JJ; Deng YZ; Wang K; Xie D; Cheng SQ
Cell Physiol Biochem; 2018; 47(4):1643-1654. PubMed ID: 29945155
[TBL] [Abstract][Full Text] [Related]
10. A Positive TGF-β/c-KIT Feedback Loop Drives Tumor Progression in Advanced Primary Liver Cancer.
Rojas A; Zhang P; Wang Y; Foo WC; Muñoz NM; Xiao L; Wang J; Gores GJ; Hung MC; Blechacz B
Neoplasia; 2016 Jun; 18(6):371-86. PubMed ID: 27292026
[TBL] [Abstract][Full Text] [Related]
11. Maintenance of stemness by miR-589-5p in hepatocellular carcinoma cells promotes chemoresistance via STAT3 signaling.
Long J; Jiang C; Liu B; Dai Q; Hua R; Chen C; Zhang B; Li H
Cancer Lett; 2018 Jun; 423():113-126. PubMed ID: 29196128
[TBL] [Abstract][Full Text] [Related]
12. Increased expression of claudin-17 promotes a malignant phenotype in hepatocyte via Tyk2/Stat3 signaling and is associated with poor prognosis in patients with hepatocellular carcinoma.
Sun L; Feng L; Cui J
Diagn Pathol; 2018 Sep; 13(1):72. PubMed ID: 30219077
[TBL] [Abstract][Full Text] [Related]
13. A 2-Benzylmalonate Derivative as STAT3 Inhibitor Suppresses Tumor Growth in Hepatocellular Carcinoma by Upregulating β-TrCP E3 Ubiquitin Ligase.
Peng T; Wonganan O; Zhang Z; Yu J; Xi R; Cao Y; Suksamrarn A; Zhang G; Wang F
Int J Mol Sci; 2021 Mar; 22(7):. PubMed ID: 33805945
[TBL] [Abstract][Full Text] [Related]
14. FAM134B induces tumorigenesis and epithelial-to-mesenchymal transition via Akt signaling in hepatocellular carcinoma.
Zhang ZQ; Chen J; Huang WQ; Ning D; Liu QM; Wang C; Zhang L; Ren L; Chu L; Liang HF; Fan HN; Zhang BX; Chen XP
Mol Oncol; 2019 Apr; 13(4):792-810. PubMed ID: 30556279
[TBL] [Abstract][Full Text] [Related]
15. DEPTOR induces a partial epithelial-to-mesenchymal transition and metastasis via autocrine TGFβ1 signaling and is associated with poor prognosis in hepatocellular carcinoma.
Chen J; Zhu H; Liu Q; Ning D; Zhang Z; Zhang L; Mo J; Du P; Liu X; Song S; Fan Y; Liang H; Liu J; Zhang B; Chen X
J Exp Clin Cancer Res; 2019 Jun; 38(1):273. PubMed ID: 31228948
[TBL] [Abstract][Full Text] [Related]
16. STEAP3 promotes cancer cell proliferation by facilitating nuclear trafficking of EGFR to enhance RAC1-ERK-STAT3 signaling in hepatocellular carcinoma.
Wang LL; Luo J; He ZH; Liu YQ; Li HG; Xie D; Cai MY
Cell Death Dis; 2021 Nov; 12(11):1052. PubMed ID: 34741044
[TBL] [Abstract][Full Text] [Related]
17. STAT3 activation mediates epithelial-to-mesenchymal transition in human hepatocellular carcinoma cells.
Zhang CH; Guo FL; Xu GL; Jia WD; Ge YS
Hepatogastroenterology; 2014 Jun; 61(132):1082-9. PubMed ID: 26158169
[TBL] [Abstract][Full Text] [Related]
18. PAK1 promotes proliferation, migration and invasion of hepatocellular carcinoma by facilitating EMT via directly up-regulating Snail.
Cao F; Yin LX
Genomics; 2020 Jan; 112(1):694-702. PubMed ID: 31071459
[TBL] [Abstract][Full Text] [Related]
19. EFTUD2 maintains the survival of tumor cells and promotes hepatocellular carcinoma progression via the activation of STAT3.
Tu M; He L; You Y; Li J; Yao N; Qu C; Huang W; Xu L; Luo R; Hong J
Cell Death Dis; 2020 Oct; 11(10):830. PubMed ID: 33024090
[TBL] [Abstract][Full Text] [Related]
20. miR-345 inhibits tumor metastasis and EMT by targeting IRF1-mediated mTOR/STAT3/AKT pathway in hepatocellular carcinoma.
Yu M; Xue H; Wang Y; Shen Q; Jiang Q; Zhang X; Li K; Jia M; Jia J; Xu J; Tian Y
Int J Oncol; 2017 Mar; 50(3):975-983. PubMed ID: 28098858
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
